DEA’s Proposed Rules on Telemedicine Controlled Substances Prescribing after the PHE Ends
This guide provided by Foley & Lardner summarizes the key elements and requirements contained in the proposed rule. In addition it explains how it differs from the special telemedicine registration rule. Finally, it describes what stakeholders can do to make their voice heard, including by submitting comments to the proposed rule, during these next 30 days.